MedPath

Analysis of Motor Performance in Children with Duchene's Muscular Dystrophy

Not yet recruiting
Conditions
Duchene's Muscular Dystrophy
Registration Number
NCT06750042
Lead Sponsor
Cairo University
Brief Summary

25 boys, ages ranging from 6 to 16 years, diagnosed with Duchene's muscular Dystrophy (DMD) will participated in the study. They will be selected from the Pediatric Rehabilitation Center of Deraya University's outpatient clinic in El-Minia district, Minia-Egypt. The outcome will be assessed motor performance will be assed by Bruininks-Oseretsky Test of Motor Proficiency Second Edition (BOT™-2) : balance, running speed and agility, bilateral coordination and strength and by Blue Cherry; Geratherm Respiratory. It is used to measure vital capacity (VC), forced expired volume in one second (FEV1), FEV1/FVC, FEV1/VC, and peak expiratory flow (PEF) to provide objective information for monitoring lung health.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
25
Inclusion Criteria
  • the diagnosis is Duchene's muscular Dystrophy only not other types,
  • ambulated with or without assistance,
  • oriented and endurance enough to understand orders to perform ventilation on the Blue Cherry; Geratherm Respiratory device.
Exclusion Criteria
  • any cognitive or neurological condition (other than Duchene's muscular Dystrophy),
  • history of previous surgical operations that can affect pulmonary functions, and structural scoliosis

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
motor performancemeasured for one time

motor performance will be assessed by Bruininks-Oseretsky Test of Motor Proficiency Second Edition (BOT™-2)

respiratory functionmeasured for only one time

respiratory function by Blue Cherry; Geratherm Respiratory. It is used to measure respiratory function to provide objective information for monitoring lung health.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath